(Q35597057)

9 August 2017

1 reference

title

A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents (English)

1 reference

9 August 2017

Lerro KA

1

1 reference

9 August 2017

Medoff E

2

1 reference

9 August 2017

Wu Y

3

1 reference

9 August 2017

Seropian SE

4

1 reference

9 August 2017

Snyder E

5

1 reference

9 August 2017

Krause D

6

1 reference

9 August 2017

Cooper DL

7

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

Bone Marrow Transplantation

9 August 2017

published in

1 reference

9 August 2017

volume

32

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

1113-1117

1 reference

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Estimation of the progenitor cell yield in a leukapheresis product by previous measurement of CD34+ cells in the peripheral blood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704286

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704286

1 reference

9 August 2017

1 reference